EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach

Laura M Güdemann, Katie G Young, Nicholas J M Thomas, Rhian Hopkins, Robert Challen, Angus G Jones, Andrew T Hattersley, Ewan R Pearson, Beverley M Shields, Jack Bowden, John M Dennis, Andrew P McGovern und 1 weitere

Diabetologia · 2024-09 · 67 (9) · 1817-1827

DOI: 10.1007/s00125-024-06190-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetologia, online erschienen am 05.06.2024. Verfasst von Laura M Güdemann und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical & Clinical Science, University of Exeter Medical School, Exeter, UK. l.guedemann@exeter.ac.uk. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, EFSD/Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/hypothesis Older adults are under-represented in trials, meaning the benefits and risks of glucose-lowering agents in this age group are unclear. The aim of this study was to assess the safety and effectiveness of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in people with type 2 diabetes aged over 70 years using causal analysis. Methods Hospital-linked UK primary care data (Clinical Practice Research Datalink, 2013–2020) were used to compare adverse events and effectiveness in individuals initiating SGLT2i compared with dipeptidyl peptidase-4 inhibitors (DPP4i). Analysis was age-stratified:

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsHumansAgedFemaleMaleUnited KingdomAged, 80 and overHypoglycemic AgentsDiabetic KetoacidosisTreatment OutcomeMiddle Aged

Stichwörter der Autor:innen

Causal analysisEffectivenessOlder adultsSGLT2 inhibitorsSafety

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Institute of Biomedical & Clinical Science, University of Exeter Medical School, Exeter, UK. l.guedemann@exeter.ac.uk.
  • Institute of Biomedical & Clinical Science, University of Exeter Medical School, Exeter, UK.
  • Division of Molecular & Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.

Förderung

  • Medical Research Council
  • EFSD/Novo Nordisk

Zitieren

APA

Güdemann, L. M., Young, K. G., Thomas, N. J. M., Hopkins, R., Challen, R., Jones, A. G., Hattersley, A. T., Pearson, E. R., Shields, B. M., Bowden, J., Dennis, J. M., McGovern, A. P., & MASTERMIND consortium (2024). Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach. Diabetologia, 67(9), 1817-1827. https://doi.org/10.1007/s00125-024-06190-9

Vancouver

Güdemann LM, Young KG, Thomas NJM, Hopkins R, Challen R, Jones AG, et al. Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach. Diabetologia. 2024;67(9):1817-1827. doi:10.1007/s00125-024-06190-9

BibTeX
@article{Gdemann2024,
  author = {Güdemann, Laura M and Young, Katie G and Thomas, Nicholas J M and Hopkins, Rhian and Challen, Robert and Jones, Angus G and Hattersley, Andrew T and Pearson, Ewan R and Shields, Beverley M and Bowden, Jack and Dennis, John M and McGovern, Andrew P and MASTERMIND consortium, MASTERMIND consortium},
  title = {Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach},
  journal = {Diabetologia},
  year = {2024},
  volume = {67},
  number = {9},
  pages = {1817--1827},
  doi = {10.1007/s00125-024-06190-9}
}
Kostenlos starten →